Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112
Open Access
- 1 September 2023
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 21 (9) , 915-923.e1
Abstract
Background: Observational data investigating the relationship between body habitus and outcomes in breast cancer have been variable and inconsistent, largely centered in the curative setting and focused on weight-based metrics. This study evaluated the impact of muscle measures on outcomes in patients with metastatic breast cancer receiving endocrine-based therapy. Methods: Baseline CT scans were collected from ECOG-ACRIN E2112, a randomized phase III placebo-controlled study of exemestane with or without entinostat. A CT cross-sectional image at the L3 level was extracted to obtain skeletal muscle mass and attenuation. Low muscle mass (LMM) was defined as skeletal muscle index 2/m2 and low muscle attenuation (LMA) as muscle density t tests. Results: Analyzable CT scans and follow-up data were available for 540 of 608 patients. LMM was present in 39% (n=212) of patients and LMA in 56% (n=301). Those with LMA were more likely to have obesity and worse performance status. LMM was not associated with survival (PFS hazard ratio [HR]: 1.13, P=.23; OS HR: 1.05, P=.68), nor was LMA (PFS HR: 1.01, P=.93; OS HR: 1.00, P=.99). BMI was not associated with survival. LMA, but not LMM, was associated with increased frequency of patient-reported muscle aches. Conclusions: Both low muscle mass and density are prevalent in patients with hormone receptor–positive metastatic breast cancer. Muscle measures correlated with obesity and performance status; however, neither muscle mass nor attenuation were associated with prognosis. Further work is needed to refine body composition measurements and select optimal cutoffs with meaningful endpoints in specific breast cancer populations, particularly those living with metastatic disease.Keywords
This publication has 19 references indexed in Scilit:
- Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled TrialJournal of Clinical Oncology, 2018
- Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia?Oncotarget, 2017
- Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapyThe Breast, 2017
- Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based ChemotherapyClinical Cancer Research, 2017
- A comparative study of software programmes for cross‐sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2016
- The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the LiteratureThe Oncologist, 2016
- Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic reviewEuropean Journal of Cancer, 2016
- Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass IndexJournal of Clinical Oncology, 2013
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008